GB0922085D0 - Cancer diagnosis and treatment - Google Patents

Cancer diagnosis and treatment

Info

Publication number
GB0922085D0
GB0922085D0 GBGB0922085.6A GB0922085A GB0922085D0 GB 0922085 D0 GB0922085 D0 GB 0922085D0 GB 0922085 A GB0922085 A GB 0922085A GB 0922085 D0 GB0922085 D0 GB 0922085D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cancer diagnosis
diagnosis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0922085.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB0922085.6A priority Critical patent/GB0922085D0/en
Publication of GB0922085D0 publication Critical patent/GB0922085D0/en
Priority to JP2012543894A priority patent/JP2013514074A/ja
Priority to US13/516,749 priority patent/US20120304318A1/en
Priority to PCT/GB2010/002294 priority patent/WO2011073629A2/en
Priority to EP10803264A priority patent/EP2512601A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB0922085.6A 2009-12-17 2009-12-17 Cancer diagnosis and treatment Ceased GB0922085D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0922085.6A GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment
JP2012543894A JP2013514074A (ja) 2009-12-17 2010-12-17 癌の診断および処置
US13/516,749 US20120304318A1 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment
PCT/GB2010/002294 WO2011073629A2 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment
EP10803264A EP2512601A2 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0922085.6A GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment

Publications (1)

Publication Number Publication Date
GB0922085D0 true GB0922085D0 (en) 2010-02-03

Family

ID=41717134

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0922085.6A Ceased GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment

Country Status (5)

Country Link
US (1) US20120304318A1 (enExample)
EP (1) EP2512601A2 (enExample)
JP (1) JP2013514074A (enExample)
GB (1) GB0922085D0 (enExample)
WO (1) WO2011073629A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
KR101445560B1 (ko) 2012-05-10 2014-09-29 한국수력원자력 주식회사 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자
KR101416147B1 (ko) 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
EP4219765B1 (en) 2012-08-16 2024-12-18 Veracyte SD, Inc. Prostate cancer prognosis using biomarkers
CA2915653A1 (en) * 2013-03-14 2014-10-02 Genomedx Biosciences, Inc. Cancer biomarkers and classifiers and uses thereof
WO2018027091A1 (en) 2016-08-05 2018-02-08 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
JP2021128140A (ja) * 2020-06-30 2021-09-02 株式会社ヤマト 漏水監視システム
CN113957152A (zh) * 2021-12-14 2022-01-21 浙江大学 一种snhg6基因的检测试剂盒及其应用
CN114592007B (zh) * 2022-04-29 2023-10-27 昆明理工大学 Far1基因的新用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
WO1994021787A1 (en) 1993-03-15 1994-09-29 Cell Genesys, Inc. Method for defined deletions of dna
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
EP1112361A2 (en) * 1998-09-14 2001-07-04 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20040138161A1 (en) * 2002-07-24 2004-07-15 Bruno Amati Methods of modulating proliferative conditions
GB0224436D0 (en) 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP2011885B1 (en) * 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE476529T1 (de) * 2005-07-08 2010-08-15 Siemens Healthcare Diagnostics Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
AU2007207341B2 (en) * 2006-01-20 2012-05-10 Women's & Children's Health Research Institute Incorporated Method of treatment, prophylaxis and diagnosis of pathologies of the bone
EP2028492A4 (en) 2006-06-05 2009-06-10 Shimadzu Corp TUMOR MARKERS AND METHOD FOR DETERMINING THE IMPACT OF ANY CANNULAR DISEASE
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US7759542B2 (en) * 2007-08-01 2010-07-20 National Yang-Ming University Glycine N-methyltransferase (GNMT) animal model and use thereof

Also Published As

Publication number Publication date
US20120304318A1 (en) 2012-11-29
WO2011073629A2 (en) 2011-06-23
WO2011073629A3 (en) 2011-08-11
EP2512601A2 (en) 2012-10-24
JP2013514074A (ja) 2013-04-25

Similar Documents

Publication Publication Date Title
GB0922085D0 (en) Cancer diagnosis and treatment
IL218575A0 (en) Treatment of cancer
EP2412297A4 (en) ENDOSCOPE OF A TYPE OF CASE FOR TREATMENT, AND ENDOSCOPE CASE
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
ZA201107390B (en) Diagnostic devices and related methods
EP2412328A4 (en) MEDICAL TREATMENT DEVICE
IL221035A0 (en) Cancer diagnosis and imaging
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
IL214133A0 (en) Skin treatment
IL222958A0 (en) Cancer treatment
GB0918392D0 (en) Diagnostic and therapeutic methods
GB2465907B (en) VHZ for diagnosis and treatment of cancer
GB0900599D0 (en) Treatment
PT2630475T (pt) Método de diagnóstico e tratamento
GB0901837D0 (en) Cancer diagnosis and treatment
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
GB0913968D0 (en) Treatment
GB0916686D0 (en) Treatment of cancer
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201001521D0 (en) Treatment
GB0809046D0 (en) Cancer treatment
GB0907098D0 (en) Cancer treatment and diagnosis
GB0813352D0 (en) Cancer treatment and test
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB0915801D0 (en) Theraputic treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)